Where to buy Osimertinib (Tagressa) and where to buy it

Osimertinib is an oral targeted therapy drug that is a third-generation epidermal growth factor receptor (EGFR) inhibitor. It is designed to treat non-small cell lung cancer (NSCLC), especially EGFR mutation-positive advanced NSCLC patients.

Osimertinib is now available in the domestic market and has also been included in the medical insurance system. Patients purchase it from domestic hospitals, and its price fluctuates between four and five thousand yuan. However, please note that specific prices and detailed policies for medical insurance reimbursement will vary by region and hospital. It is recommended that you consult your local hospital or pharmacy to obtain the most accurate information.

If you consider a more economical option, foreign generic drugs of osimertinib provide a cost-effective option. In particular, the price of generic drugs produced in Laos and Bangladesh is only about a few hundred yuan, which is significantly lower than in the domestic market. It is worth mentioning that these generic drugs are highly consistent with the domestic original drugs in terms of pharmaceutical ingredients, so they have similar efficacy. If you are considering purchasing a generic drug, make sure it comes from a legitimate source to ensure the quality and safety of the drug.

As a highly selective drug, osimertinib exerts its effect mainly by inhibitingEGFRkinase activity. EGFR is a key cell surface receptor that plays an important role in tumor cell growth and proliferation. EGFRmutations are a common molecular abnormality in NSCLC patients, especially in Asian populations. By inhibiting the activity of EGFR mutations, osimertinib can effectively inhibit the proliferation and growth of tumor cells, thereby prolonging the survival of patients.

Compared with first- and second-generation EGFR inhibitors, osimertinib has higher selectivity and stronger anti-tumor activity, and can effectively overcome common EGFR resistance mutations, such as T790M mutations. This makes osimertinib one of the first-choice treatments for patients with EGFR T790M-positive advanced NSCLC.

In general, osimertinib, as a targeted therapy, has demonstrated significant efficacy and safety inNSCLC patients. It provides an effective treatment option for patients with advanced NSCLC and makes an important contribution to improving patients' survival rate and quality of life. With further understanding of its mechanism of action and clinical application, osimertinib is expected to continue to play an important role in the treatment of lung cancer in the future.